EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial

Masaki Matsushita iD, Hiroshi Kitoh, Takuo Kubota, Keita Okada, Kenichi Mishima, Kenta Sawamura, Taichi Kitaoka, Makoto Fujiwara, Yuichi Kato, Yuri Amano, Kazuki Nishida, Shiro Imagama

Calcified Tissue International · 01.12.2025 · 116 (1)

DOI: 10.1007/s00223-025-01449-8 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Calcified Tissue International, online erschienen am 01.12.2025. Verfasst von Masaki Matsushita und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. matsushita.masaki.a7@f.mail.nagoya-u.ac.jp. Hauptthemen laut MEDLINE: Achondroplasia, Meclizine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meclizine has been shown to promote bone growth by inhibiting a key signaling pathway involved in achondroplasia (ACH). Earlier studies demonstrated its safety in children with ACH after short-term use. The purpose of this study is to assess the safety and efficacy of meclizine treatment over 26 weeks in children with ACH. This open-label, single-arm, Phase 2 study was conducted at four sites in Japan. Nine children with ACH, aged 5-10 years old, received daily meclizine (12.5 mg/day for those < 20 kg; 25 mg/day for those ≥ 20 kg). This was co-administered with growth hormone therapy for 26 weeks. Safety was monitored through adverse events (AEs), while treatment efficacy was measured by changes in height velocity (cm/year). Secondary measures included the proportion of children achieving a height velocity of ≥ 6 cm/year and changes in arm span growth. Arm span velocity and the proportion of participants reaching ≥ 6 cm/year were evaluated through ad hoc analyses. No serious AEs were reported. Height velocity increased slightly from 4.35 ± 1.36 cm/year pre-treatment to 4.46 ± 1.54 cm/year post-treatment. One participant achieved a height velocity of ≥ 6 cm/year. Mean height increased from 107.48 ± 9.04 to 109.77 ± 8.69 cm over the study period. By contrast, arm span velocity was higher at 6.93 ± 2.50 cm/year, with six children reaching ≥ 6 cm/year. An additive effect of meclizine and growth hormone on promoting height was not observed; however, meclizine may enhance arm span growth in children with ACH.Trial registration number jRCT2041230001.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AchondroplasiaMeclizineHumansChildChild, PreschoolMaleFemaleTreatment OutcomeAdministration, OralBody Height

Stichwörter der Autor:innen

AchondroplasiaArm spanFibroblast growth factor receptor 3HeightMeclizine

Substanzen

Meclizine

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. matsushita.masaki.a7@f.mail.nagoya-u.ac.jp.
  • Department of Orthopaedic Surgery, Aichi Children's Health and Medical Center, Obu, Japan.
  • Department of Comprehensive Pediatric Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Japan.
  • Department of Pediatric Nephrology and Metabolism, Osaka Women's and Children's Hospital, Osaka Prefectural Hospital Organization, Izumi, Japan.
  • Department of Orthopaedic Surgery, The University of Tokyo Hospital, Tokyo, Japan.

ORCID-Profile: Masaki Matsushita

Zitieren

APA

Matsushita, M., Kitoh, H., Kubota, T., Okada, K., Mishima, K., Sawamura, K., Kitaoka, T., Fujiwara, M., Kato, Y., Amano, Y., Nishida, K., & Imagama, S. (2025). Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial. Calcified Tissue International, 116(1). https://doi.org/10.1007/s00223-025-01449-8

Vancouver

Matsushita M, Kitoh H, Kubota T, Okada K, Mishima K, Sawamura K, et al. Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial. Calcified Tissue International. 2025;116(1). doi:10.1007/s00223-025-01449-8

BibTeX
@article{Matsushita2025,
  author = {Matsushita, Masaki and Kitoh, Hiroshi and Kubota, Takuo and Okada, Keita and Mishima, Kenichi and Sawamura, Kenta and Kitaoka, Taichi and Fujiwara, Makoto and Kato, Yuichi and Amano, Yuri and Nishida, Kazuki and Imagama, Shiro},
  title = {Efficacy and Safety of Oral Meclizine for Growth Promotion in Children with Achondroplasia: A Phase 2 Clinical Trial},
  journal = {Calcified Tissue International},
  year = {2025},
  volume = {116},
  number = {1},
  doi = {10.1007/s00223-025-01449-8}
}
Kostenlos starten →